• Profile

Lower risk of HCC in chronic hepatitis B patients treated with tenofovir vs entecavir

Journal of Gastroenterology and Hepatology Jan 28, 2022

NOTE, original article title: Lower risk of HCC with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: An updated meta‐analysis

In view of the controversial results from the previous smaller meta-analyses comparing the incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) vs entecavir (ETV), researchers conducted this updated meta-analysis with the aim to reliably identify if TDF and ETV treated CHB patients, in general or in specific subgroups, differ in terms of the HCC incidence.

  • From PubMed, EMBASE, Web of Science, and Cochrane Library, researchers identified 24 comparative studies involving 37,771 CHB patients treated with TDF and 72,094 treated with ETV for inclusion.

  • Evidence gained suggests an association of TDF with significantly reduced HCC risk compared with ETV treatment in patients who are from Asia and/or nucleos(t)ide naïve.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen